Current Report Filing (8-k)
July 28 2016 - 7:36AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported):
July
28, 2016
ARIAD
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
001-36172
|
22-3106987
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(I.R.S.
Employer
Identification
No.)
|
26 Landsdowne Street, Cambridge,
Massachusetts
|
02139
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant's telephone number, including
area code:
(617) 494-0400
Not Applicable
(Former name
or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions
(
see
General Instruction A.2.
below)
:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM 2.02
|
Results of Operations and Financial Condition.
|
In a press release dated July 28, 2016, ARIAD Pharmaceuticals, Inc. (the
“Company”) announced financial results for the second quarter and six
months ended June 30, 2016 and provided an update on corporate
developments. A copy of the press release is attached hereto as Exhibit
99.1. The information under the headings “Financial Results for the
Quarter and Six Months Ended June 30, 2016”, “Today’s Conference Call at
8:30 a.m. ET” and the condensed consolidated financial information
included in the press release are incorporated by reference into this
Item 2.02 of this Current Report on Form 8-K.
ITEM 7.01
|
Regulation FD Disclosure.
|
In the press release dated July 28, 2016, the Company also provided
information on upcoming medical meetings. The information set forth
under the heading “Upcoming Medical Meetings” in the press release is
incorporated by reference into this Item 7.01 of this Current Report on
Form 8-K.
In the press release dated July 28, 2016, the Company also provided an
update on its Iclusig
®
, brigatinib and pipeline
programs. The second paragraph of the press release and the information
set forth under the heading “Recent Progress and Key Objectives,”
together with the forward-looking statement disclaimer at the end of the
press release, are incorporated by reference into this Item 8.01 of this
Current Report on Form 8-K.
ITEM 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
Exhibit
|
|
Description
|
|
99.1
|
|
Press release dated July 28, 2016
|
The press release may contain hypertext links to information on our
websites. The information on our websites is not incorporated by
reference into this Current Report on Form 8-K and does not constitute a
part of this Form 8-K.
The portions of the press release incorporated by reference into Item
8.01 of this Current Report on Form 8-K are being filed pursuant to such
item. The remaining portions of the press release are being furnished
pursuant to Items 2.02 and 7.01 of this Current Report on Form 8-K and
shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise
subject to the liabilities of that Section, nor shall they be deemed
incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act except as shall be expressly set
forth by specific reference in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
ARIAD Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Manmeet S. Soni
|
|
|
|
|
|
Manmeet S. Soni
|
|
|
|
|
|
Executive Vice President, Chief Financial Officer
|
|
|
|
|
|
Date:
|
July 28, 2016
|
|
|
|
Exhibit Index
Exhibit Number
|
Description
|
|
|
99.1
|
Press release dated July 28, 2016
|
4
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Apr 2023 to Apr 2024